A

Advance Medical Research Center | Miami, FL

Research site

(Unclaimed)

Location

330 South West 27th Avenue, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

M5049

GED-0301

Empagliflozin

Lorecivivint

695501

BMS-986446

TRx0237

SM04690

AVP-786

Diltiazem Hydrochloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (empacific)

This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM).The study dur...

Enrolling

Myositis

Dermatomyositis

Other: Placebo IV

Biological: Empasiprubart IV

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting

Alzheimer's Disease

Drug: Piromelatine 20 mg

Drug: Placebo

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus...

Enrolling

Systemic Lupus Erythematosus

Drug: M5049 medium dose

Drug: M5049 low dose